Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma
- 15 January 2008
- journal article
- review article
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 65 (2) , 123-131
- https://doi.org/10.2146/ajhp060661
Abstract
Purpose. The role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma (mRCC) is reviewed.Keywords
This publication has 27 references indexed in Scilit:
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agentsBJU International, 2006
- Sunitinib in Patients With Metastatic Renal Cell CarcinomaJAMA, 2006
- Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- Renal-Cell CarcinomaNew England Journal of Medicine, 2005
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and AngiogenesisCancer Research, 2004
- Phase iii randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinomaCancer, 1995
- Von Hippel-Lindau disease: a genetic study.Journal of Medical Genetics, 1991